In the latest in Our Milestones series, we look at how Cancer Research UK scientists helped develop one of the world’s most successful cancer drugs.
We explore new data showing that cancer survival in England remains lower than countries with similar healthcare systems.
It’s taken years of frustration and dedication (not to mention countless hours spent in a small room roughly the temperature…
How our researchers in Manchester are helping develop ways to make chemotherapy kinder and more effective.
In light of a preliminary ‘no’ from NICE over olaparib for ovarian cancer, we hear from one of our experts whose work led to the drug’s development
We look at headlines about a new blood test for ovarian cancer, and why a possible routine screening test for the disease is still some way off.
Our researchers are investigating the genetic ‘patchwork’ underlying ovarian tumours, which will lead to more effective treatments in the future.
A Lethal Weapon against cancer? Researchers are using ‘synthetic lethality’ to develop new treatments based on targeting DNA repair processes.
Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK?
To coincide with the publication of our Annual Review, here are some of the key research milestones that our amazing supporters have helped fund.